Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.82 |
| ▸ | CCND1 | P24385 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24398975 | 1.00 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL29368287 | 1.00 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL28236962 | 0.98 | CDK4 (0.81) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL30701168 | 0.93 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL4992403 | 0.93 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL30063707 | 0.85 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL734246 | 0.85 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| Phosphoric Acid SCHEMBL6511008 | 0.85 | CDK4 (0.66) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL27518021 | 0.83 | CDK4 (0.73) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL9702210 | 0.82 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041725-A1 | HAIR CARE COMPOSITIONS COMPRISING MALODOR REDUCTION MATERIALS | PROCTER & GAMBLE (US) | 2024-02-08 | — | — | US | claimed |
| US-20220175640-A1 | HAIR CARE COMPOSITIONS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | claimed |
| US-20180360706-A1 | Delivery Particles | PROCTER & GAMBLE (US) | 2018-12-20 | — | — | US | claimed |
| EP-2563508-A2 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2013-03-06 | — | — | EP | claimed |
| CN-102892492-A | Delivery particle | PROCTER & GAMBLE | 2013-01-23 | — | — | CN | claimed |
| US-20110268802-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY | 2011-11-03 | — | — | US | claimed |
| WO-2010079468-A2 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | claimed |
| EP-4747001-A2 | SILICA CAPSULES | The Procter & Gamble Company (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12478942-B2 | Methods of making capsules | THE PROCTER & GAMBLE COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4255375-B1 | HAIR CARE COMPOSITION COMPRISING MALODOR REDUCTION MATERIALS | PROCTER & GAMBLE (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3955890-B1 | CAPSULES | PROCTER & GAMBLE (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12343696-B2 | Capsules | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250107973-A1 | SILICA CAPSULES | THE PROCTER & GAMBLE COMPANY | 2025-04-03 | — | — | US | disclosed |
| US-20110269658-A1 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110269657-A1 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110268778-A1 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY | 2011-11-03 | — | — | US | disclosed |
| WO-2010084480-A2 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010079466-A2 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079468-A2 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079467-A2 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250107973-A1 | SILICA CAPSULES | SRI, MCM4, RCC1 | CDK4 1436/4885CCND1 708/4885LMNA 1662/4885 |
| US-20180360706-A1 | Delivery Particles | LIPA, CHMP4B, ABCB4 | CDK4 4122/4885CCND1 3663/4885LMNA 1590/4885 |
| US-20110268802-A1 | DELIVERY PARTICLE | LIPA, CHMP4B, SLC46A1 | CDK4 4092/4885CCND1 3602/4885LMNA 1581/4885 |
| US-20110268778-A1 | DELIVERY PARTICLES | LIPA, CHMP4B, ABCB4 | CDK4 4122/4885CCND1 3663/4885LMNA 1590/4885 |
| US-12478942-B2 | Methods of making capsules | FUT6, FUT5, LIPA | CDK4 1893/4885CCND1 3471/4885LMNA 1124/4885 |
| US-20110269658-A1 | DELIVERY PARTICLES | LIPA, CHMP4B, ABCB4 | CDK4 4122/4885CCND1 3663/4885LMNA 1590/4885 |
| US-20110269657-A1 | DELIVERY PARTICLES | LIPA, CHMP4B, ABCB4 | CDK4 4122/4885CCND1 3663/4885LMNA 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.